Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) have received an average rating of “Hold” from the nineteen research firms that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $40.04.

Several research firms have recently weighed in on JUNO. Maxim Group reaffirmed a “buy” rating and issued a $56.00 target price (up previously from $34.00) on shares of Juno Therapeutics in a report on Monday, October 9th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $44.00 target price on shares of Juno Therapeutics in a report on Friday, October 6th. Morgan Stanley reiterated an “equal weight” rating and set a $43.00 price target (up previously from $27.00) on shares of Juno Therapeutics in a research report on Friday, October 6th. Barclays PLC started coverage on shares of Juno Therapeutics in a research report on Wednesday, September 6th. They set an “overweight” rating and a $55.00 price target on the stock. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $54.00 price target (up previously from $35.00) on shares of Juno Therapeutics in a research report on Tuesday, September 5th.

In other Juno Therapeutics news, EVP Robert Azelby sold 12,850 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $44.95, for a total transaction of $577,607.50. Following the transaction, the executive vice president now directly owns 37,439 shares in the company, valued at approximately $1,682,883.05. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Sunil Agarwal sold 7,285 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $44.76, for a total transaction of $326,076.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 85,004 shares of company stock worth $3,551,561. Corporate insiders own 15.26% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in JUNO. The Manufacturers Life Insurance Company lifted its position in Juno Therapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 228 shares during the period. Pacad Investment Ltd. acquired a new position in Juno Therapeutics during the 2nd quarter valued at about $105,000. QS Investors LLC acquired a new position in Juno Therapeutics during the 2nd quarter valued at about $135,000. Great West Life Assurance Co. Can lifted its position in Juno Therapeutics by 80.5% during the 1st quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 3,800 shares during the period. Finally, Macquarie Group Ltd. acquired a new position in Juno Therapeutics during the 2nd quarter valued at about $248,000. Institutional investors own 67.50% of the company’s stock.

Shares of Juno Therapeutics (NASDAQ JUNO) opened at 44.49 on Wednesday. The company’s market capitalization is $4.67 billion. The company has a 50-day moving average of $43.59 and a 200 day moving average of $31.40. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $47.03.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm had revenue of $21.30 million during the quarter, compared to the consensus estimate of $15.59 million. During the same period in the previous year, the company posted ($0.64) EPS. The firm’s revenue for the quarter was down 22.8% compared to the same quarter last year. Analysts forecast that Juno Therapeutics will post ($3.08) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/25/juno-therapeutics-inc-juno-given-consensus-recommendation-of-hold-by-brokerages.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.